Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus NOVOLOG FLEXTOUCH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus NOVOLOG FLEXTOUCH.
HUMALOG MIX 50/50 PEN vs NOVOLOG FLEXTOUCH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on liver, muscle, and adipose tissue, promoting glucose uptake and storage, and inhibiting hepatic glucose production.
Insulin analog with rapid onset and short duration of action; binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic glucose production.
Subcutaneous injection, 0.5 to 1 unit/kg/day divided into two doses (before breakfast and before dinner), individualized based on blood glucose levels.
Subcutaneous injection; typical adult dose is 0.5-1 unit/kg/day divided into multiple doses; for type 1 diabetes, administered 5-10 minutes before meals with a basal insulin; for type 2 diabetes, initial dose 4 units or 0.1-0.2 units/kg with meals.
None Documented
None Documented
Terminal half-life: 0.5-1.0 hour (insulin lispro); clinical context: short duration due to rapid clearance.
1.5-2 hours (subcutaneous); terminal elimination half-life: 1.8 hours
Renal: 75-80% as metabolites; hepatic: 20-25% via biliary elimination.
Renal: ~60% as unchanged drug and metabolites; biliary/fecal: ~40%
Category C
Category C
Insulin Analog
Insulin Analog